Please upgrade your browser.
The findings from this consortiumbased study do not support the hypothesis that vitamin D is inversely associated with the risk of kidney cancer overall or with renal cell carcinoma specifically.
Combined Renal Sinus Fat and Perinephric Fat Renal Cell Carcinoma Invasion Has a Worse Prognosis Than Either Alone
Patients with combined renal sinus and perinephric fat invasion had a worse prognosis than those with either alone. Considerations should be made to stage these cases accordingly.
Development and External Validation of a Nomogram Predicting Disease Specific Survival After Nephrectomy for Papillary Renal Cell Carcinoma
The authors developed a highly accurate tool specifically for papillary renal cell carcinoma using basic clinical and pathological information to predict disease specific survival. This tool should be helpful to identify papillary renal cell carcinoma with aggressive clinical behavior and may contribute to the ability to individualize postoperative surveillance and therapy.
Research findings, 'Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient,' are discussed in a new report. In this recently published article, scientists in the United States conducted a study "To determine whether iatrogenic immunosuppression used after transplantation infers a poor prognosis of renal cell carcinoma (RCC) as natural negative immune regulators have been associated with decreased cancer-specific survival from RCC. All patients with a solid organ transplant who underwent radical nephrectomy or nephron-sparing surgery for nonhereditary sporadic RCC from 1970 to 2003 were identified and retrospectively reviewed."
In an editorial accompanying the data in Lancet Oncology, Steven E. Nissen, MD, of the department of medicine, Cleveland Clinic, called the meta-analysis disturbing and proactive.
Aveo Pharmaceuticals Inc., a Cambridge biotech firm, said the European Medicines Agency has granted orphan status to one of its experimental drugs.
The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.
Background: Multiple new therapies are now approved for patients (pts) with advanced RCC. As these agents enter widespread use, their perceived toxicities may differ from those reported in the literature and limit treatment duration and clinical outcomes. Patient reporting of toxicities may more accurately identify side effects most relevant to patients.
An Acreage couple have filed a lawsuit against Pratt & Whitney, blaming the defense contractor for the wife's kidney cancer amid a state probe of an unsolved cancer cluster in their community.
Doctors should monitor patients taking bevacizumab (Avastin), researchers say.
|Powered by NeonCRM|